Targeting inflammation and cytokine storm in COVID-19

Pharmacol Res. 2020 Sep:159:105051. doi: 10.1016/j.phrs.2020.105051. Epub 2020 Jun 27.
No abstract available

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • COVID-19 Drug Treatment
  • Cell Cycle Proteins / antagonists & inhibitors
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / immunology
  • Coronavirus Infections / virology
  • Cytokines / metabolism*
  • Host Microbial Interactions / drug effects
  • Host Microbial Interactions / immunology
  • Humans
  • Immunologic Factors / therapeutic use
  • Inflammasomes / drug effects
  • Inflammasomes / immunology
  • Inflammation / drug therapy*
  • Inflammation / immunology
  • Inflammation / virology
  • Interleukin-6 / antagonists & inhibitors
  • Models, Immunological
  • NLR Family, Pyrin Domain-Containing 3 Protein / antagonists & inhibitors
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / immunology
  • Pneumonia, Viral / virology
  • SARS-CoV-2
  • Transcription Factors / antagonists & inhibitors

Substances

  • Anti-Inflammatory Agents
  • BRD4 protein, human
  • Cell Cycle Proteins
  • Cytokines
  • IL6 protein, human
  • Immunologic Factors
  • Inflammasomes
  • Interleukin-6
  • NLR Family, Pyrin Domain-Containing 3 Protein
  • NLRP3 protein, human
  • Transcription Factors